BioCryst Pharmaceuticals, Inc.
(NASDAQ : BCRX)

( )
BCRX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.44%185.971.2%$605.33m
CELGCelgene Corporation
0.00%78.801.2%$532.62m
GILDGilead Sciences, Inc.
0.00%71.070.9%$518.63m
BIIBBiogen Inc.
0.00%296.041.2%$437.32m
NKTRNektar Therapeutics
0.00%52.855.6%$412.99m
SRPTSarepta Therapeutics, Inc.
0.00%140.3316.6%$356.37m
VRTXVertex Pharmaceuticals Incorporated
0.00%159.191.9%$269.27m
REGNRegeneron Pharmaceuticals, Inc.
0.00%331.972.6%$248.01m
ILMNIllumina, Inc.
0.00%282.653.5%$212.82m
BLUEBluebird Bio, Inc.
-0.53%168.0015.7%$193.26m
EXASExact Sciences Corporation
0.00%66.3325.4%$180.98m
AAgilent Technologies, Inc.
0.00%62.791.5%$178.44m
ALXNAlexion Pharmaceuticals, Inc.
0.00%127.572.0%$159.93m
BMRNBioMarin Pharmaceutical Inc.
0.00%99.034.4%$141.99m
INCYIncyte Corporation
0.00%74.032.5%$133.28m

Company Profile

BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The firm focusses on oral treatments for rare diseases. Its portfolio includes Rapivab, Kallikrein inhibitors, and BCX4430. These drugs intend to treat influenza and hereditary angioedema. The company was founded in 1986 and is headquartered in Durham, NC.